INOVIQ LTD — Board/Management Information 2016

Nov 2, 2016

==> picture [155 x 46] intentionally omitted <==

BARD1 APPOINTS CHIEF EXECUTIVE OFFICER

Perth, Australia, 3 November 2016: Australian life sciences company BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 or the Company ) is pleased to announce the appointment of Dr Leearne Hinch as Chief Executive Officer, commencing Monday 7[th] November 2016.

Dr Leearne Hinch is a biotechnology executive and consultant with over 20 years’ experience in the life sciences industry across general management, strategy, fundraising, business development and technology commercialisation. Leearne is currently director of commercialisation advisory Ingeneus Solutions, and has previously held CEO and executive positions in ASX-listed biotechnology, multinational and private companies including Eustralis Pharmaceuticals Ltd, Immuron Ltd, OBJ Ltd, Holista CollTech Ltd and Virbac (Australia) Pty Ltd.

Leearne has strategic, operational and technical experience leading and managing the development and commercialisation of multiple drug, device and animal health products. She has a track record in biotechnology leadership, driving performance and achieving results including advancing development milestones, raising funds and securing partners to deliver organisational growth, increased revenues and improved valuations. Leearne holds a Master of Business Administration from Curtin University, Bachelor of Science and Bachelor of Veterinary Medicine and Surgery degrees from Murdoch University, and is a member of the Accelerating Commercialisation Expert Network.

Regarding her appointment, Leearne said: “I am gratified to join BARD1 at this important stage in its development, and look forward to working with the Board and management to realize the full potential of the BARD1 technology as both a diagnostic marker and therapeutic target, advancing the BARD1 Lung Cancer Test towards the clinical validation milestone, and expanding our pipeline opportunities”.

BARD1 Executive Chairman, Peter Gunzburg said “The Board welcomes the appointment of Leearne Hinch as CEO to strengthen our executive management team. She brings the leadership, technical and commercial experience required to lead the Company forward as we commercialise our BARD1 technology, progress our development programs and grow shareholder value.”

- ENDS -

FOR MORE INFORMATION, PLEASE CONTACT:

Peter Gunzburg Dr Leearne Hinch Executive Chairman CEO E peter@bard1.com E leearne@bard1.com M +61 412 927 773 M +61 400 414 416

BARD1 Life Sciences Limited (ABN 59 009 070 384) Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Its proprietary BARD1 Technology is a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Its lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. It is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

ABOUT BARD1 PROTEIN & ISOFORMS

The BARD1 gene (BRCA1-associated RING domain 1) is a potent tumour suppressor coding for the protein BARD1, an important protein binding and stabilising the BRCA1 protein. Cancer cells express numerous aberrant BARD1 isoforms (mutated proteins) that induce circulating BARD1 autoantibodies. Previous published research has shown that combinations of BARD1 isotypes are specific for different cancer types and that the BARD1 autoantibodies generated can be detected early in the blood serum. Furthermore, BARD1 isotypes have been shown to be expressed in multiple epithelial cancers including lung, breast, ovarian, prostate, and colorectal cancers, and have been correlated with cancer progression and poor prognosis.